Quality of Life in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy : The Randomized NORDIC9-Study
Liposits,Gabor; Eshøj,Henrik Rode; Möller,Sören; Winther,Stine Brændegaard; Skuladottir,Halla; Ryg,Jesper; Hofsli,Eva; Shah,Carl Henrik; Poulsen,Laurids Østergaard; Berglund,Åke; Qvortrup,Camilla; Österlund,Pia; Glimelius,Bengt; Sorbye,Halfdan; Pfeiffer,Per (2021)
This publication is copyrighted. You may download, display and print it for Your own personal use. Commercial use is prohibited
Julkaisun pysyvä osoite on
Quality of life data from randomized trials are lacking in older patients with metastatic colorectal cancer (mCRC). In the randomized NORDIC9-study, reduced-dose S1+oxaliplatin (SOx) showed superior efficacy compared to full-dose S1 monotherapy. We hypothesized that treatment with SOx does not result in inferior quality of life. Patients with mCRC aged ≥ 70 years and that were not a candidate for standard combination chemotherapy were included and randomly as-signed to receive either S1 or SOx. The EORTC QLQ-C30 questionnaire was completed at baseline, after 9, and 18 weeks. The primary endpoint was global Quality of Life (QoL) at 9 weeks. For statistical analysis, a non-inferiority design was chosen applying linear mixed effects models for repeated measurements. The results were interpreted according to statistical significance and anchor-based, clinically relevant between-group minimally important differences (MID). A total of 160 patients aged (median (Interquartile range (IQR))) 78 years (76–81) were included. The QLQ-C30 questionnaire was completed by 150, 100, and 60 patients at baseline, at 9, and 18 weeks, respectively. The difference at 9 weeks in global QoL was 6.85 (95%CI-1.94; 15.65) and 7.37 (0.70; 14.05) in the physical functioning domain in favor of SOx exceeding the threshold for MID. At 18 weeks, the between-group MID in physical functioning was preserved. Dose-reduced combination chemotherapy may be recommended in vulnerable older patients with mCRC, rather than full-dose monotherapy.
- TUNICRIS-julkaisut 
Näytetään aineisto, joilla on samankaltaisia nimekkeitä, tekijöitä tai asiasanoja.
Smirnov,Sergey; Gotchev,Atanas; Hannuksela,Miska
IEEE International Conference on Multimedia and Expo (2013)
Joint de-noising and fusion of 2D video and depth map sequences sensed by low-powered tof range sensor Georgiev,Mihail; Gotchev,Atanas; Hannuksela,Miska
IEEE International Conference on Multimedia and Expo (Institute of Electrical and Electronics Engineers IEEE, 2013)
Georgiev,Mihail; Gotchev,Atanas; Hannuksela,Miska
IEEE International Symposium on Circuits and Systems (Institute of Electrical and Electronics Engineers IEEE, 2013)